Your fact-checks will appear here
Organization
Older adults may face greater practical and clinical risks from repeated ivermectin use because they have higher use rates and more concurrent medications that can interact with ivermectin; authoritat...
Available reporting and studies through the provided sources show that vaccine hesitancy and lower COVID-19 vaccine uptake in the 2020s clustered by geography (notably parts of sub‑Saharan Africa), by...
Peer-reviewed, long-term (3–5+ year) studies specifically designed to follow people from COVID-19 vaccination through three to five or more years are limited in the public record; most large safety ef...
Unapproved “detox” regimens promoted for vaccine side effects can pose health risks, especially if they delay medical care or involve untested ingredients; mainstream public-health sources emphasize t...
Available sources show major health authorities do not recommend ivermectin to prevent or treat COVID‑19 and that research has produced mixed, largely negative or low‑quality signals for its effective...
Updated COVID-19 vaccines introduced for 2024–2025 and adjusted again for 2025 target recent Omicron descendants (JN.1, KP.2, LP.8.1 and related lineages) and provide clear protection against severe o...
Available reporting shows a core distinction: direct detection of spike protein or spike-encoding vaccine mRNA after vaccination is generally described as transient (days–weeks) in public-health and m...
The FDA authorizes ivermectin for a small set of parasitic indications and warns it is not approved for COVID‑19; human oral tablets (now available in 3 mg and 6 mg strengths) are dosed by weight for ...
Studies and reviews show both SARS‑CoV‑2 infection and COVID‑19 vaccination can leave detectable spike protein or spike fragments in blood or tissues for longer than early models predicted; reports do...
Modern U.S. COVID-19 vaccines are complex products whose full ingredient lists are provided in official package inserts and CDC product information; the CDC’s interim clinical considerations explicitl...
Ivermectin has been evaluated in multiple randomized trials and systematic reviews, and the aggregated evidence through early 2025 shows , though some trials report modest symptom shortening. Systemat...
Yes: the preponderance of independent, peer‑reviewed evidence through 2025–2026 finds COVID‑19 vaccines to be safe and effective at reducing serious illness and hospitalization, though protection agai...
A reported 30–40% relative reduction in infection risk means that a person’s chance of getting infected is multiplied by 0.60–0.70 compared with the unprotected baseline; the actual change in their ab...
Official guidance from major public-health bodies addresses some timing issues — for example, CDC and ACIP set vaccine dose intervals and clinical considerations for when to vaccinate relative to proc...
Seek medical help for low body temperature (hypothermia) after flu or COVID if you have ongoing confusion, difficulty breathing, chest pain, fainting, or your temperature is persistently very low — es...
Available reporting in the provided documents shows Anthony (Tony) Fauci retired from federal service in December 2022 and has since appeared in public events, lectures and private engagements; multip...
Regulatory bodies approve ivermectin for human parasitic infections at standard oral doses around 150–200 µg/kg (0.15–0.2 mg/kg) for one or two doses, and do not authorize it for prevention or treatme...
Guidelines converge on mandatory screening for Strongyloides stercoralis in patients who are, or will be, immunosuppressed and who have epidemiologic risk (residence or travel to endemic areas, or oth...
The 2025–2026 COVID-19 vaccines—formulated to match recent Omicron-lineage viruses—continue to show meaningful protection, especially against hospitalization and death, and public-health agencies endo...
Peer‑reviewed, end‑of‑season estimates specifically labeled “2025–26 end‑of‑season” remain limited in the literature, but a systematic NEJM review of studies through July 31, 2025 concluded that ongoi...